Show Summary Details
Page of

Hodgkin lymphoma 

Hodgkin lymphoma
Hodgkin lymphoma

Isabella Maund

and Michael Williams

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 January 2021

The management of early Hodgkin lymphoma is an area of evolving practice. Investigation should be aimed at fully staging and risk stratifying patients in order to guide treatment decisions. Standard treatment is a combined modality approach including involved-field radiotherapy. However, recent trials have highlighted the issue of fatal late-effects including the risks of second malignancy and cardiovascular disease attributed to radiotherapy. Treatment strategies based on chemotherapy alone have been suggested as an alternative to radiation-based treatment. Whilst chemotherapy alone may provide improved overall survival due to reduction in non-lymphoma mortality, it is associated with an increased risk of relapse requiring extensive salvage therapy and patients must be carefully counselled regarding the risks and benefit of both approaches.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.